[Clinical response to combined treatment with reaferon and iodantipirin in patients with chronic HCV- and HBV-infection].
The treatment was given to 100 patients with chronic virus hepatitis of moderate activity and chronicity stage I. Of them, 50 patients received reaferon (3 IU 3 times a week) in combination with antiviral and immunomodulating drug iodantipirin (100 mg/d) given on the days of reaferon injections for 6 months. The other 50 patients received reaferon alone in the same doses and duration of the treatment course. Efficiency was assessed by the level of ALT, findings at polymerase chain reaction, index of histological activity of hepatic biopsy. The combined scheme demonstrated higher efficiency and tolerance.
Beloborodova
E I
EI
Vnushinskaia
M A
MA
Rachkovskiĭ
M I
MI
Shalovaĭ
A A
AA
Timoshchuk
O A
OA
Khudoleĭ
N V
NV
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D017613:Iodine Compounds / Q000627:therapeutic use; D008297:Male; D011720:Pyrazoles / Q000627:therapeutic use; D047069:Pyrazolones; D011994:Recombinant Proteins
C459160:1-phenyl-2,3-dimethyl-4-iodopyrazolone; D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007369:Interferon Inducers; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D017613:Iodine Compounds; D011720:Pyrazoles; D047069:Pyrazolones; D011994:Recombinant Proteins